200 related articles for article (PubMed ID: 3933351)
21. A randomized crossover comparison of two low-dose contraceptives: effects on serum lipids and lipoproteins.
März W; Gross W; Gahn G; Romberg G; Taubert HD; Kuhl H
Am J Obstet Gynecol; 1985 Oct; 153(3):287-93. PubMed ID: 2931988
[TBL] [Abstract][Full Text] [Related]
22. A comparative metabolic study of two low-estrogen-dose oral contraceptives containing desogestrel or gestodene progestins.
Crook D; Godsland IF; Worthington M; Felton CV; Proudler AJ; Stevenson JC
Am J Obstet Gynecol; 1993 Nov; 169(5):1183-9. PubMed ID: 8238183
[TBL] [Abstract][Full Text] [Related]
23. Plasma glucose and insulin levels in women using a levonorgestrel-containing triphasic oral contraceptive for three months.
Spellacy WN; Ellingson AB; Kotlik A; Tsibris JC
Contraception; 1988 Jul; 38(1):27-35. PubMed ID: 3139358
[TBL] [Abstract][Full Text] [Related]
24. Plasma lipoproteins and fatty acid composition after "minipill".
Sassolas A; Lagarde M; Guichardant M; Quincy C; Dechavanne M
Contraception; 1983 Oct; 28(4):357-68. PubMed ID: 6421540
[TBL] [Abstract][Full Text] [Related]
25. Lipid and lipoprotein changes in women taking low-dose, triphasic oral contraceptives: a controlled, comparative, 12-month clinical trial.
Notelovitz M; Feldman EB; Gillespy M; Gudat J
Am J Obstet Gynecol; 1989 May; 160(5 Pt 2):1269-80. PubMed ID: 2655452
[TBL] [Abstract][Full Text] [Related]
26. Plasma lipids and high density lipoproteins during oral contraception with different combinations of ethinyl estradiol and levonorgestrel.
Larsson-Cohn U; Wallentin L; Zador G
Horm Metab Res; 1979 Jul; 11(7):437-40. PubMed ID: 225252
[TBL] [Abstract][Full Text] [Related]
27. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism.
Oelkers W; Foidart JM; Dombrovicz N; Welter A; Heithecker R
J Clin Endocrinol Metab; 1995 Jun; 80(6):1816-21. PubMed ID: 7775629
[TBL] [Abstract][Full Text] [Related]
28. Carbohydrate metabolic studies in women using a levonorgestrel/ethinyl estradiol containing triphasic oral contraceptive for eighteen months.
Spellacy WN; Tsibris JC; Ellingson AB
Int J Gynaecol Obstet; 1991 May; 35(1):69-71. PubMed ID: 1680079
[TBL] [Abstract][Full Text] [Related]
29. Low-dose oral contraceptives lower plasma levels of apolipoprotein E.
Steinmetz A; Bauer K; Jürgensen R; Kaffarnik H
Eur J Obstet Gynecol Reprod Biol; 1990 Nov; 37(2):155-62. PubMed ID: 2147014
[TBL] [Abstract][Full Text] [Related]
30. Comparison of the metabolic effects of two hormonal contraceptive methods: an oral formulation and a vaginal ring. I. Carbohydrate metabolism and liver function.
Ahrén T; Victor A; Lithell H; Johansson ED
Contraception; 1981 Oct; 24(4):415-27. PubMed ID: 6797784
[TBL] [Abstract][Full Text] [Related]
31. Low dosage oral contraception in women with previous gestational diabetes.
Skouby SO; Mølsted-Pedersen L; Kühl C
Obstet Gynecol; 1982 Mar; 59(3):325-8. PubMed ID: 6804901
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of a monophasic and a triphasic oral contraceptive containing norgestimate.
Corson SL
Am J Obstet Gynecol; 1994 May; 170(5 Pt 2):1556-61. PubMed ID: 8178906
[TBL] [Abstract][Full Text] [Related]
33. Effects of three combined oral contraceptive preparations containing desogestrel plus ethinyl estradiol on lipid metabolism in comparison with two levonorgestrel preparations.
Kloosterboer HJ; Rekers H
Am J Obstet Gynecol; 1990 Jul; 163(1 Pt 2):370-3. PubMed ID: 2142577
[TBL] [Abstract][Full Text] [Related]
34. Metabolic effects of the triphasic oral contraceptive Trigynon.
Vermeulen A; Thiery M
Contraception; 1982 Nov; 26(5):505-13. PubMed ID: 6761061
[TBL] [Abstract][Full Text] [Related]
35. Prospective evaluation of insulin resistance and lipid metabolism in women receiving oral contraceptives.
Sheu WH; Hsu CH; Chen YS; Jeng CY; Fuh MM
Clin Endocrinol (Oxf); 1994 Feb; 40(2):249-55. PubMed ID: 8137525
[TBL] [Abstract][Full Text] [Related]
36. Oral contraceptives: effects on glucose and lipid metabolism in insulin-dependent diabetic women and women with previous gestational diabetes. A clinical and biochemical assessment.
Skouby SO
Dan Med Bull; 1988 Apr; 35(2):157-67. PubMed ID: 3282811
[TBL] [Abstract][Full Text] [Related]
37. Clinical chemistry in women treated with levonorgestrel implants (Norplant) or a TCu 200 IUD.
Croxatto HB; Diaz S; Robertson DN; Pavez M
Contraception; 1983 Mar; 27(3):281-8. PubMed ID: 6406139
[TBL] [Abstract][Full Text] [Related]
38. Oral contraceptives and coronary heart disease: modulation of glucose tolerance and plasma lipid risk factors by progestins.
Crook D; Godsland IF; Wynn V
Am J Obstet Gynecol; 1988 Jun; 158(6 Pt 2):1612-20. PubMed ID: 3287933
[TBL] [Abstract][Full Text] [Related]
39. Metabolic studies in gestational diabetic women during contraceptive treatment: effects on glucose tolerance and fatty acid composition of serum lipids.
Rådberg T; Gustafson A; Skryten A; Karlsson K
Gynecol Obstet Invest; 1982; 13(1):17-29. PubMed ID: 7035304
[TBL] [Abstract][Full Text] [Related]
40. Comparative trial of the effects on glucose tolerance and lipoprotein metabolism of two new oral contraceptives containing gestoden and desogestrel.
Rubeck Petersen K; Skouby SO; Dreisler A; Kühl C; Svenstrup B
Acta Obstet Gynecol Scand; 1988; 67(1):37-41. PubMed ID: 2972158
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
